Cellectar Biosciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

12 Months Ended

Dec. 31, 2023

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities consist of the following as of December 31:


		2023			2022

Incentive compensation		$	2,069,000		$	916,000
Accounts payable			5,620,000			2,558,000
Clinical project costs			1,252,000			1,637,000
Professional fees			153,000			359,000
Other			85,000			8,000
		$	9,179,000		$	5,478,000